ISSN: 1309 - 3843 E-ISSN: 1307 - 7384
FİZİKSEL TIP VE REHABİLİTASYON
BİLİMLERİ DERGİSİ
www.jpmrs.com
Kayıtlı İndexler


ORIJINAL ARAŞTIRMA

COVID-19 Pandemi Sürecinde Hastanede İntravenöz Biyolojik Ajan Tedavilerinin Güvenirliği
Patient Compliance and Safety of Intravenous Biological Drug Treatments in Hospital During the COVID-19 Pandemic
Received Date : 21 Jun 2021
Accepted Date : 08 Dec 2021
Available Online : 20 Dec 2021
Doi: 10.31609/jpmrs.2021-85092 - Makale Dili: EN
J PMR Sci. 2022;25(2):158-65
ÖZET
Amaç: Bu çalışmanın amacı, inflamatuar romatizmal veya bağırsak hastalıkları olan hastalarda, koronavirüs hastalığı-2019 [coronavirus disease-2019 (COVID-19)] pandemisi sırasında hastanede intravenöz (IV) biyolojik ilaçların güvenliğini ve tedavi uyumunu değerlendirmektir. Gereç ve Yöntemler: Hastaların kayıtları 11.03.2020-30.09.2020 tarihleri arasında hastane elektronik veri tabanından geriye dönük olarak tarandı. İnflamatuar romatizmal veya bağırsak hastalığı olan ve IV biyolojik tedavi uygulanan hastalar çalışmaya dâhil edildi. Demografik ve klinik verilerle COVID-19 enfeksiyonuna ilişkin bilgiler kaydedildi. Bulgular: Çalışmaya dâhil edilen 103 hastanın yaş ortalaması 45,3 (minimum-maksimum: 18-76 yıl) ve 53’ü (%51,5) kadındı. Hastaların çoğunluğu (87 hasta, %84,5) ankilozan spondilit, romatoid artrit, ülseratif kolit ve Crohn hastalığından oluşuyordu. Pandemi döneminde, 77 (%74,8) hasta rutin takibe devam etti, 18 (%17,5) hasta takip aralığını uzattı ve 8 (%7,7) hasta takibi bıraktı. On iki (%11,6) hastada sekonder yanıtsızlık, alerjik reaksiyon veya ilaç bulunamaması nedeniyle biyolojik ajanlar değiştirildi. Bu dönemde, 6 hastaya COVID-polimeraz zincir reaksiyonu [polymerase chain reaction (PCR)] testi yapıldı ve 2 hastada pozitif çıktı. Bunlar sırasıyla romatoid artrit ve sistemik skleroz tanısı ile infliksimab ve rituksimab tedavisi alıyorlardı. COVID-19 tedavisinin sonunda da aynı tedaviye devam ettiler. Sonuç: Bu çalışma, hastaların çoğunun rutin takip ve tedaviye devam ettiğini ve bu tedavilerin COVID-19 riskini artırmadığını göstermiştir. Bu nedenle IV biyolojik tedavilerin pandemi sürecinde güvenle kullanılabileceğini düşünüyoruz.
ABSTRACT
Objective: To evaluate compliance and safety of treatments with intravenous (IV) biological drugs in hospital during the coronavirus disease-2019 (COVID-19) pandemic in patients with inflammatory rheumatic or bowel diseases. Material and Methods: The records of patients were retrospectively scanned from the hospital electronic database between 11.03.2020-30.09.2020. The patients with inflammatory rheumatic or bowel diseases who received IV biological therapy were included in the study. Demographic and clinic data, and information about COVID-19 infection were recorded. Results: The mean age of 103 patients included in the study was 45.3 years (minimum-maximum: 18-76 years) and 53 (51.5%) were women. The majority of patients (87 patients, 84.5%) consisted of ankylosing spondylitis, rheumatoid arthritis, ulcerative colitis, and Crohn’s disease. During the pandemic period, 77 (74.8%) patients continued routine follow-up, 18 (17.5%) patients extended the interval between visits, and 8 (7.7%) patients stopped follow-up. The biological drugs were switched to another in 12 (11.6%) patients due to secondary unresponsiveness, allergic reaction or unavailable drug. In this period, 6 patients were made COVID-polymerase chain reaction test and it was positive in 2 patients. They were receiving infliximab and rituximab treatment with the diagnosis of rheumatoid arthritis and systemic sclerosis, respectively. They continued the same treatment at the end of COVID-19 treatment. Conclusion: This study showed that most of the patients continued to routine follow-up and treatment, and these treatments did not increase the risk of COVID-19. Therefore, we think that IV biological treatments can be safely used during the pandemic process.
REFERENCES
  1. Burrage DR, Koushesh S, Sofat N. Immunomodulatory drugs in the management of SARS-CoV-2. Front Immunol. 2020;11: 1844. [Crossref]  [PubMed]  [PMC] 
  2. Sepriano A, Kerschbaumer A, Smolen JS, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2020;79:760-70. [Crossref]  [PubMed] 
  3. Monti S, Balduzzi S, Delvino P, et al. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis. 2020;79:667-8. [Crossref]  [PubMed]  [PMC] 
  4. Baddley JW, Cantini F, Goletti D, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents). Clin Microbiol Infect. 2018;24 Suppl 2:S10-S20. [Crossref]  [PubMed] 
  5. Paules CI, Marston HD, Fauci AS. Coronavirus infections-more than just the common cold. JAMA. 2020;323:707-8. [Crossref]  [PubMed] 
  6. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565-74. [PubMed]  [PMC] 
  7. Khan N, Patel D, Xie D, et al. Impact of anti-tumor necrosis factor and thiopurine medications on the development of COVID-19 in patients with inflammatory bowel disease: A nationwide veterans administration cohort study. Gastroenterology. 2020;159:1545-6.e1. [Crossref]  [PubMed]  [PMC] 
  8. Accortt NA, Bonafede MM, Collier DH, et al. Risk of subsequent infection among patients receiving tumor necrosis factor inhibitors and other disease-modifying antirheumatic drugs. Arthritis Rheumatol. 2016;68:67-76. [Crossref]  [PubMed] 
  9. Kastritis E, Kitas GD, Vassilopoulos D, et al. Systemic autoimmune diseases, anti-rheumatic therapies, COVID-19 infection risk and patient outcomes. Rheumatol Int. 2020;40:1353-60. [Crossref]  [PubMed]  [PMC] 
  10. Bonfá E, Gossec L, Isenberg DA, et al. How COVID-19 is changing rheumatology clinical practice. Nat Rev Rheumatol. 2021;17:11-5. [Crossref]  [PubMed]  [PMC] 
  11. Gheita TA, Salem MN, Eesa NN, et al; ECR COVID19-Study Group. Rheumatologists' practice during the Coronavirus disease 2019 (COVID-19) pandemic: a survey in Egypt. Rheumatol Int. 2020;40:1599-611. [Crossref]  [PubMed]  [PMC] 
  12. Mikuls TR, Johnson SR, Fraenkel L, et al. American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 1. Arthritis Rheumatol. 2020; 72:1241-51. [Crossref]  [PubMed] 
  13. Brito CA, Paiva JG, Pimentel FN, et al. COVID-19 in patients with rheumatological diseases treated with anti-TNF. Ann Rheum Dis. 2021;80:e62. [Crossref]  [PubMed] 
  14. Rutherford AI, Subesinghe S, Hyrich KL, et al. Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis. 2018;77:905-10. [Crossref]  [PubMed] 
  15. Singh S, Facciorusso A, Dulai PS, et al. Comparative risk of serious infections with biologic and/or immunosuppressive therapy in patients with inflammatory bowel diseases: A systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2020;18:69-81.e3. [Crossref]  [PubMed]  [PMC] 
  16. Duret PM, Sebbag E, Mallick A, et al. Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept. Ann Rheum Dis. 2020;79:1251-2. [Crossref]  [PubMed]  [PMC] 
  17. Neurath MF. COVID-19 and immunomodulation in IBD. Gut. 2020;69:1335-42. [Crossref]  [PubMed]  [PMC] 
  18. Sanchez-Piedra C, Diaz-Torne C, Manero J, et al; BIOBADASER study group. Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies. Ann Rheum Dis. 2020;79:988-90. [Crossref]  [PubMed]  [PMC] 
  19. Haberman R, Axelrad J, Chen A, et al. Covid-19 in immune-mediated inflammatory diseases-case series from New York. N Engl J Med. 2020;383:85-8. [Crossref]  [PubMed]  [PMC] 
  20. Peyrin-Biroulet L, Danese S. More on Covid-19 in immune-mediated inflammatory diseases. N Engl J Med. 2020;383:796. [Crossref]  [PubMed] 
  21. Tay MZ, Poh CM, Rénia L, et al. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20:363-74. [Crossref]  [PubMed]  [PMC] 
  22. Li G, Fan Y, Lai Y, et al. Coronavirus infections and immune responses. J Med Virol. 2020;92:424-32. [Crossref]  [PubMed]  [PMC] 
  23. Haga S, Yamamoto N, Nakai-Murakami C, et al. Modulation of TNF-alpha-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-alpha production and facilitates viral entry. Proc Natl Acad Sci U S A. 2008;105:7809-14. [Crossref]  [PubMed]  [PMC] 
  24. Fisher CJ Jr, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med. 1996;334:1697-702. [Crossref]  [PubMed] 
  25. Mehta P, McAuley DF, Brown M, et al; HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033-4. [Crossref]  [PubMed]  [PMC] 
  26. Feldmann M, Maini RN, Woody JN, et al. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. Lancet. 2020;395:1407-9. [Crossref]  [PubMed]  [PMC] 
  27. Conti P, Ronconi G, Caraffa A, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents. 2020;34:327-31. [PubMed] 
  28. Zhang C, Wu Z, Li JW, et al. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents. 2020;55:105954. [Crossref]  [PubMed]  [PMC] 
  29. Reuters [Internet]. ©2021 Reuters [Cited: ]. Roche provides an update on the phase III COVACTA trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 associated pneumonia. 02.03.2021 Available from: [Link] 
  30. Guaraldi G, Meschiari M, Cozzi-Lepri A, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol. 2020;2:e474-e84. Erratum in: Lancet Rheumatol. 2020;2:e591. [PubMed]  [PMC] 
  31. Ng SC, Hilmi IN, Blake A, et al. Low frequency of opportunistic infections in patients receiving vedolizumab in clinical trials and post-marketing setting. Inflamm Bowel Dis. 2018; 24:2431-41. [Crossref]  [PubMed]  [PMC] 
  32. Pateinakis P, Pyrpasopoulou A. CD20+ B cell depletion in systemic autoimmune diseases: common mechanism of inhibition or disease-specific effect on humoral immunity? Biomed Res Int. 2014;2014:973609. [Crossref]  [PubMed]  [PMC] 
  33. Kow CS, Hasan SS. Use of rituximab and the risk of adverse clinical outcomes in COVID-19 patients with systemic rheumatic disease. Rheumatol Int. 2020;40:2117-8. [Crossref]  [PubMed]  [PMC] 
  34. Loarce-Martos J, García-Fernández A, López-Gutiérrez F, et al. High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: A descriptive study. Rheumatol Int. 2020;40:2015-21. [Crossref]  [PubMed]  [PMC] 
  35. Batu ED, Lamot L, Sag E, et al. How the COVID-19 pandemic has influenced pediatric rheumatology practice: Results of a global, cross-sectional, online survey. Semin Arthritis Rheum. 2020;50:1262-8. [Crossref]  [PubMed]  [PMC] 
  36. Gupta L, Misra DP, Agarwal V, et al. Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology practitioners from India. Ann Rheum Dis. 2021;80:e1. [Crossref]  [PubMed] 
  37. Ziadé N, Hmamouchi I, El Kibbi L, et al. The impact of COVID-19 pandemic on rheumatology practice: a cross-sectional multinational study. Clin Rheumatol. 2020;39:3205-13. [Crossref]  [PubMed]  [PMC] 
  38. Krusche M, Mühlensiepen F, Aries P, et al. Telemedizin in der rheumatologie [Telemedicine in rheumatology]. Z Rheumatol. 2020;79:883-92. German. [Crossref]  [PubMed]  [PMC] 
  39. Akintayo RO, Akpabio AA, Kalla AA, et al. The impact of COVID-19 on rheumatology practice across Africa. Rheumatology (Oxford). 2021;60:392-8. [Crossref]  [PubMed]  [PMC] 
  40. Cai K, He J, Wong PK, et al. The impact of COVID-19 on rheumatology clinical practice and university teaching in Sydney, Australia. Eur J Rheumatol. 2020;7:S91-S3. [Crossref]  [PubMed]  [PMC]